CBD के लिए अनिद्रा

References

1. [1] Richard I Shader. J Clin Psychopharmacol. Question: Is it safe for people with cancer and other serious conditions to combine cannabidiol with melatonin when neither has … doi:10.1097/JCP.0000000000002024 PubMed
2. [2] Michael Hsu et al.. JAMA. 2026. Therapeutic Use of Cannabis and Cannabinoids: A Review. doi:10.1001/jama.2025.19433 PubMed
3. [3] Anastasia Suraev et al.. J Sleep Res. 2026. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. doi:10.1111/jsr.70124 PubMed
4. [4] Karina Fatakhova et al.. JGH Open. 2026. Cannabidiol Use in Inflammatory Bowel Disease: Insights From a Gastroenterology Outpatient Population. doi:10.1002/jgh3.70402 PubMed
5. [5] Jack Wilson et al.. Lancet Psychiatry. 2026. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and … doi:10.1016/S2215-0366(26)00015-5 PubMed
6. [6] Luis E Gomez Wulschner et al.. Cannabis Cannabinoid Res. 2026. Oral Consumption of Cannabidiol During Pregnancy Alters Behavior in Mouse Offspring. doi:10.1177/25785125251413416 PubMed
7. [7] Thomas R Arkell et al.. Trials. 2026. Effects of prescribed medical cannabis and alcohol on real-world driving performance (CAN-TRACK): a study protocol for a two-phase trial. doi:10.1186/s13063-026-09512-x PubMed
8. [8] Michael Wang et al.. J Clin Sleep Med. 2025. Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. doi:10.5664/jcsm.11324 PubMed
9. [9] Xiangwen Li et al.. BMC Pregnancy Childbirth. 2025. Trends in burden and mortality of congenital birth defects in G20 countries (1990-2021) and predictions for 2022-2040. doi:10.1186/s12884-025-07617-w PubMed
10. [10] Nora de Bode et al.. Clin Psychol Rev. 2025. The differential effects of medicinal cannabis on mental health: A systematic review. doi:10.1016/j.cpr.2025.102581 PubMed
11. [11] Daniela Iezzi et al.. Transl Psychiatry. 2025. Sex-specific disruptions in the developmental trajectory of anxiety-like behaviors due to prenatal cannabidiol exposure. doi:10.1038/s41398-025-03517-x PubMed
12. [12] Andrea J Narayan et al.. Psychopharmacology (Berl). 2025. The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot … doi:10.1007/s00213-024-06674-x PubMed
13. [13] Luis E Gomez Wulschner et al.. bioRxiv. 2025. Consumption of clinically relevant cannabidiol doses during pregnancy alters postnatal behavior in offspring. doi:10.1101/2025.04.30.651495 PubMed
14. [14] Sara R Till et al.. J Obstet Gynaecol Can. 2025. Cannabidiol Use and Perceptions of Effectiveness in Women With Chronic Pelvic Pain. doi:10.1016/j.jogc.2025.102839 PubMed
15. [15] Ioana Creangă-Murariu et al.. Curr Oncol Rep. 2025. Indications of Cannabinoids for the Palliation of Cancer-Associated Symptoms: A Systematic Review and Meta-Analysis. doi:10.1007/s11912-025-01695-x PubMed
16. [16] Anas Ibn Auf et al.. Psychopharmacol Bull. 2025. Cannabidiol Induced Manic Episode: A Case Report. doi:10.64719/pb.4542 PubMed
17. [17] Aragon F et al.. J Pain Palliat Care Pharmacother. 2025. Effectiveness of Full Spectrum Cannabis Extracts in the Treatment of Chronic Pain: An Open Label Study. doi:10.1080/15360288.2025.2517778 PubMed
18. [18] Nora Satybaldiyeva et al.. J Cannabis Res. 2025. Prevalence and reasons for using cannabidiol, delta-8 tetrahydrocannabinol, cannabinol, cannabigerol, and hexahydrocannabinol among US adults. doi:10.1186/s42238-025-00359-8 PubMed
19. [19] Nicole M G Fleege et al.. Clin Breast Cancer. 2025. Characterizing Cannabidiol Use in a Breast Cancer Population. doi:10.1016/j.clbc.2025.02.003 PubMed
20. [20] Heather Hausenblas et al.. Health Sci Rep. 2025. Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot … doi:10.1002/hsr2.70481 PubMed
21. [21] Myfanwy Graham et al.. Neuropsychopharmacol Rep. 2025. NSW cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development. doi:10.1002/npr2.12498 PubMed
22. [22] Bohong Zheng et al.. Pharmaceuticals (Basel). 2025. Unraveling Cannabidiol's Bidirectional Regulation of Melatonin Pharmacokinetics via PEPT1/CYP1A2: Mechanistic Insights and Quantitative Projections. doi:10.3390/ph19010080 PubMed
23. [23] Giovanna Hanike Santos da Silva et al.. Sleep Med Rev. 2025. Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: A systematic review and … doi:10.1016/j.smrv.2025.102156 PubMed
24. [24] Philip M Finch et al.. Pain Manag. 2025. Opioid reduction in patients with chronic non-cancer pain undergoing treatment with medicinal cannabis. doi:10.1080/17581869.2025.2544511 PubMed
25. [25] Aglaia Vignoli et al.. Epilepsia Open. 2025. Is highly purified cannabidiol a treatment opportunity for drug-resistant epilepsy in subjects with typical Rett syndrome and CDKL5 deficiency disorder? doi:10.1002/epi4.70078 PubMed
26. [26] Sérgio Mota-Rolim et al.. Prog Brain Res. 2025. Green light to sleep: Does cannabis work for insomnia? A case report and brief review. doi:10.1016/bs.pbr.2025.07.005 PubMed
27. [27] Chen Gou et al.. Front Pharmacol. 2025. Real-world disproportionality analysis of sleep disturbances associated with antiseizure medications in epilepsy: a pharmacovigilance study. doi:10.3389/fphar.2025.1740747 PubMed
28. [28] Bo A D F Saals et al.. Contemp Clin Trials. 2025. Evaluating the effect of cannabidiol on sleep quality in patients with multiple sclerosis using 15 aggregated N-of-1 trials: A study … doi:10.1016/j.cct.2025.108071 PubMed
29. [29] Gabriel Rodrigues Coutinho Pereira et al.. J Cannabis Res. 2025. Assessing patient perceptions of off-label cannabidiol use for insomnia through sentiment analysis. doi:10.1186/s42238-025-00306-7 PubMed
30. [30] Estácio Amaro da Silva et al.. Trends Psychiatry Psychother. 2024. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled … doi:10.47626/2237-6089-2021-0396 PubMed
31. [31] Andrea J Narayan et al.. J Clin Sleep Med. 2024. Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. doi:10.5664/jcsm.10998 PubMed
32. [32] Katelyn F Romm et al.. J Stud Alcohol Drugs. 2024. Cannabis Retailer Communication About Cannabis Products, Health Benefits, and Risks: A Mystery Shopper Study of Licensed Retailers in Five U.S. … doi:10.15288/jsad.23-00034 PubMed
33. [33] Yu-Meng Liu et al.. Neurochem Res. 2024. Cannabidiol Exerts Sedative and Hypnotic Effects in Normal and Insomnia Model Mice Through Activation of 5-HT1A Receptor. doi:10.1007/s11064-024-04102-2 PubMed
34. [34] Martina D'Angelo et al.. Int J Mol Sci. 2024. Cannabinoids and Sleep: Exploring Biological Mechanisms and Therapeutic Potentials. doi:10.3390/ijms25073603 PubMed
35. [35] Mengxue He et al.. Cannabis Cannabinoid Res. 2024. Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes. doi:10.1089/can.2022.0331 PubMed
36. [36] Isobel Lavender et al.. Curr Psychiatry Rep. 2024. Using Cannabis and CBD to Sleep: An Updated Review. doi:10.1007/s11920-024-01564-7 PubMed
37. [37] Noemi Cárdenas-Rodríguez et al.. Int J Mol Sci. 2024. Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition. doi:10.3390/ijms25073805 PubMed
38. [38] Taylan Gurgenci et al.. Trials. 2024. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients … doi:10.1186/s13063-024-08091-z PubMed
39. [39] Anastasia Suraev et al.. Psychopharmacology (Berl). 2024. Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled … doi:10.1007/s00213-024-06595-9 PubMed
40. [40] Daniela Iezzi et al.. Cells. 2024. Gestational CBD Shapes Insular Cortex in Adulthood. doi:10.3390/cells13171486 PubMed
41. [41] Patrícia Montagner et al.. Front Pharmacol. 2024. Charting the therapeutic landscape: a comprehensive evidence map on medical cannabis for health outcomes. doi:10.3389/fphar.2024.1494492 PubMed
42. [42] Anastasia Suraev et al.. Drug Test Anal. 2024. Detection of Δ9-tetrahydrocannabinol (THC) in oral fluid using two point-of-collection testing devices following oral administration of a THC and cannabidiol … doi:10.1002/dta.3658 PubMed
43. [43] Chenshu Zhang et al.. Cannabis Cannabinoid Res. 2024. Factors Associated with Medical Cannabis Use After Certification: A Three-Month Longitudinal Study. doi:10.1089/can.2022.0248 PubMed
44. [44] Ana Carolina Ruver-Martins et al.. Front Hum Neurosci. 2024. Low doses of cannabis extract ameliorate non-motor symptoms of Parkinson's disease patients: a case series. doi:10.3389/fnhum.2024.1466438 PubMed
45. [45] Christa M Frodella et al.. Biomedicines. 2024. Oxytocin and Vasopressin Gene Expression in the Brain as Potential Biomarkers for Cannabidiol Therapeutic Efficacy. doi:10.3390/biomedicines12061273 PubMed
46. [46] Daniela Iezzi et al.. bioRxiv. 2024. Sex-specific disruptions in the developmental trajectory of anxiety due to prenatal cannabidiol exposure. doi:10.1101/2024.12.02.626301 PubMed
47. [47] Daniela Iezzi et al.. bioRxiv. 2024. Gestational CBD shapes insular cortex in adulthood. doi:10.1101/2024.06.26.597499 PubMed
48. [48] Jonathon C Arnold et al.. Clin Transl Sci. 2023. The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. doi:10.1111/cts.13425 PubMed
49. [49] Karin Ried et al.. J Sleep Res. 2023. Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. doi:10.1111/jsr.13793 PubMed
50. [50] Rylea M Ranum et al.. Cannabis Cannabinoid Res. 2023. Use of Cannabidiol in the Management of Insomnia: A Systematic Review. doi:10.1089/can.2022.0122 PubMed
51. [51] Sumit Bansal et al.. Drug Metab Dispos. 2023. A Physiologically-Based Pharmacokinetic Model for Cannabidiol in Healthy Adults, Hepatically-Impaired Adults, and Children. doi:10.1124/dmd.122.001128 PubMed
52. [52] Cornelis Jan van Dam et al.. Trials. 2023. Cannabis-opioid interaction in the treatment of fibromyalgia pain: an open-label, proof of concept study with randomization between treatment groups: cannabis, … doi:10.1186/s13063-023-07078-6 PubMed
53. [53] Sarah S Stith et al.. Front Pharmacol. 2023. Understanding feeling "high" and its role in medical cannabis patient outcomes. doi:10.3389/fphar.2023.1135453 PubMed
54. [54] Rachel Nathan et al.. Am J Hosp Palliat Care. 2023. Assessing Efficacy and Use Patterns of Medical Cannabis for Symptom Management in Elderly Cancer Patients. doi:10.1177/10499091221110217 PubMed
55. [55] Anastasia Suraev et al.. Nat Sci Sleep. 2023. Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey. doi:10.2147/NSS.S390583 PubMed
56. [56] Cassidy Scott et al.. J Clin Med. 2023. Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19-A Scoping Review. doi:10.3390/jcm13010227 PubMed
57. [57] Pulikanti Guruprasad Reddy et al.. Bioorg Chem. 2023. Novel phenolate salts of bioactive agents: Cannabidiol phenolate salts. doi:10.1016/j.bioorg.2023.106914 PubMed
58. [58] Fabrizio Calapai et al.. Pharmaceuticals (Basel). 2023. Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase. doi:10.3390/ph16101420 PubMed
59. [59] Nirushi Kuhathasan et al.. Compr Psychiatry. 2023. Predictors of perceived symptom change with acute cannabis use for mental health conditions in a naturalistic sample: A machine learning … doi:10.1016/j.comppsych.2023.152377 PubMed
60. [60] Roland Grad et al.. Am Fam Physician. 2023. Top 20 Research Studies of 2022 for Primary Care Physicians. PubMed
61. [61] Adam Strzelczyk et al.. CNS Drugs. 2022. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies. doi:10.1007/s40263-022-00955-9 PubMed
62. [62] Anna E Kirkland et al.. Psychiatry Res. 2022. A scoping review of the use of cannabidiol in psychiatric disorders. doi:10.1016/j.psychres.2021.114347 PubMed
63. [63] Isobel Lavender et al.. Chest. 2022. Cannabinoids, Insomnia, and Other Sleep Disorders. doi:10.1016/j.chest.2022.04.151 PubMed
64. [64] C Sakal et al.. Psychopharmacology (Berl). 2022. Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21. doi:10.1007/s00213-021-05855-2 PubMed
65. [65] Jeremy D Henson et al.. Inflammopharmacology. 2022. Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions. doi:10.1007/s10787-022-01020-z PubMed
66. [66] Ethan B Russo et al.. Cannabis Cannabinoid Res. 2022. Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. doi:10.1089/can.2021.0058 PubMed
67. [67] Amer Haffar et al.. J Arthroplasty. 2022. Topical Cannabidiol (CBD) After Total Knee Arthroplasty Does Not Decrease Pain or Opioid Use: A Prospective Randomized Double-Blinded Placebo-Controlled Trial. doi:10.1016/j.arth.2022.03.081 PubMed
68. [68] Bhanu Prakash Kolla et al.. J Prim Care Community Health. 2022. The Effects of Cannabinoids on Sleep. doi:10.1177/21501319221081277 PubMed
69. [69] Alistair W Vickery et al.. PLoS One. 2022. A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years. doi:10.1371/journal.pone.0272241 PubMed
70. [70] Rob Velzeboer et al.. Sleep. 2022. Cannabis dosing and administration for sleep: a systematic review. doi:10.1093/sleep/zsac218 PubMed
71. [71] Manaswini Pillai et al.. Expert Rev Neurother. 2022. Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry. doi:10.1080/14737175.2022.2155139 PubMed
72. [72] Nirushi Kuhathasan et al.. BMC Psychiatry. 2022. An investigation of cannabis use for insomnia in depression and anxiety in a naturalistic sample. doi:10.1186/s12888-022-03948-6 PubMed
73. [73] Christopher Kudrich et al.. Cannabis Cannabinoid Res. 2022. Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol. doi:10.1089/can.2021.0089 PubMed
74. [74] Sharon R Sznitman et al.. J Anxiety Disord. 2022. Posttraumatic stress disorder, sleep and medical cannabis treatment: A daily diary study. doi:10.1016/j.janxdis.2022.102632 PubMed
75. [75] Zeeta Bawa et al.. BMC Prim Care. 2022. Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021-2022 survey. doi:10.1186/s12875-022-01946-x PubMed
76. [76] Helen Senderovich et al.. Gerontology. 2022. The Effectiveness of Cannabis and Cannabis Derivatives in Treating Lower Back Pain in the Aged Population: A Systematic Review. doi:10.1159/000518269 PubMed
77. [77] Hayley Worth et al.. Clin J Am Soc Nephrol. 2022. Cannabinoids for Symptom Management in Patients with Kidney Failure: A Narrative Review. doi:10.2215/CJN.11560821 PubMed
78. [78] Laura MacNair et al.. J Cannabis Res. 2022. Medical cannabis authorization patterns, safety, and associated effects in older adults. doi:10.1186/s42238-022-00158-5 PubMed
79. [79] Flor Cristina Ortiz Rios et al.. Drugs Context. 2022. Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico. doi:10.7573/dic.2022-3-2 PubMed
80. [80] Mark Montebello et al.. Drug Alcohol Depend. 2022. Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. doi:10.1016/j.drugalcdep.2022.109388 PubMed
81. [81] G Palmieri et al.. Clin Ter. 2022. Insomnia treatment: a new multitasking natural compound based on melatonin and cannabis extracts. doi:10.7417/CT.2022.2399 PubMed
82. [82] Maria Marchese et al.. JCO Oncol Pract. 2022. Description and Disposition of Patients With Cancer Accessing a Novel, Pharmacist-Led Cannabis Consultation Service. doi:10.1200/OP.21.00748 PubMed
83. [83] Ranim Kazzaz et al.. Ann Med Surg (Lond). 2022. Laparoscopic management of a primary gallbladder hydatid cyst with daughter cysts in the common bile duct: Case report. doi:10.1016/j.amsu.2022.104165 PubMed
84. [84] Julie Moltke et al.. J Cannabis Res. 2021. Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. doi:10.1186/s42238-021-00061-5 PubMed
85. [85] Katrina Weston-Green et al.. Front Psychiatry. 2021. A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in … doi:10.3389/fpsyt.2021.583211 PubMed
86. [86] Claudio Liguori et al.. Sleep Med Rev. 2021. Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: A literature review. doi:10.1016/j.smrv.2021.101559 PubMed
87. [87] Camille Stewart et al.. JAMA Surg. 2021. Perioperative Cannabis as a Potential Solution for Reducing Opioid and Benzodiazepine Dependence. doi:10.1001/jamasurg.2020.5545 PubMed
88. [88] Nirushi Kuhathasan et al.. J Med Internet Res. 2021. The Use of Cannabinoids for Insomnia in Daily Life: Naturalistic Study. doi:10.2196/25730 PubMed
89. [89] Irene Braithwaite et al.. Curr Opin Psychol. 2021. Medicinal applications of cannabis/cannabinoids. doi:10.1016/j.copsyc.2020.06.002 PubMed
90. [90] Francis Lovecchio et al.. Int J Spine Surg. 2021. Prevalence of Cannabidiol Use in Patients With Spine Complaints: Results of an Anonymous Survey. doi:10.14444/8087 PubMed
91. [91] Alejandra Mondino et al.. Adv Exp Med Biol. 2021. Effects of Cannabis Consumption on Sleep. doi:10.1007/978-3-030-61663-2_11 PubMed
92. [92] Ganesh Gopalakrishna et al.. Neurodegener Dis Manag. 2021. Cannabinoids in the management of frontotemporal dementia: a case series. doi:10.2217/nmt-2020-0048 PubMed
93. [93] Gen-Hao Fan et al.. Zhongguo Zhong Yao Za Zhi. 2021. [Systematic evaluation and trail sequential analysis of efficacy and safety of Yangxue Qingnao Granules in treatment of essential hypertension and … doi:10.19540/j.cnki.cjcmm.20200712.501 PubMed
94. [94] Anastasia S Suraev et al.. Sleep Med Rev. 2020. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. doi:10.1016/j.smrv.2020.101339 PubMed
95. [95] Rabia Khan et al.. J Cannabis Res. 2020. The therapeutic role of Cannabidiol in mental health: a systematic review. doi:10.1186/s42238-019-0012-y PubMed
96. [96] Lara Senn et al.. Pharmaceuticals (Basel). 2020. Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Seizures and Epilepsy. doi:10.3390/ph13080174 PubMed
97. [97] Anastasia Suraev et al.. BMJ Open. 2020. Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. doi:10.1136/bmjopen-2019-034421 PubMed
98. [98] Sharon R Sznitman et al.. BMJ Support Palliat Care. 2020. Medical cannabis and insomnia in older adults with chronic pain: a cross-sectional study. doi:10.1136/bmjspcare-2019-001938 PubMed
99. [99] Maximus Berger et al.. BMJ Case Rep. 2020. Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. doi:10.1136/bcr-2020-235307 PubMed
100. [100] Tiffany J Braley et al.. Mult Scler J Exp Transl Clin. 2020. Cannabinoid use among Americans with MS: Current trends and gaps in knowledge. doi:10.1177/2055217320959816 PubMed
101. [101] Alistair W Vickery et al.. Intern Med J. 2020. Cannabis: are there any benefits? doi:10.1111/imj.15052 PubMed
102. [102] Dominique Endres et al.. Brain Sci. 2020. Parkinsonian Syndrome with Frontal Lobe Involvement and Anti-Glycine Receptor Antibodies. doi:10.3390/brainsci10060399 PubMed
103. [103] Rudolf Likar et al.. Schmerz. 2020. [Cannabidiol in cancer treatment]. doi:10.1007/s00482-019-00438-9 PubMed
104. [104] Hee Seon Park et al.. J Vet Sci. 2020. Anti-microbial and anti-inflammatory effects of Cheonwangbosim-dan against Helicobacter pylori-induced gastritis. doi:10.4142/jvs.2020.21.e39 PubMed
105. [105] Yumeng Huang et al.. Prion. 2020. Corticobasal manifestations of Creutzfeldt-Jakob disease with D178N-homozygous 129M genotype. doi:10.1080/19336896.2020.1812367 PubMed
106. [106] Carlos Alberto Hurtado González et al.. Case Rep Neurol. 2020. Neuropsychiatric Aspects in a Patient Diagnosed with Corticobasal Degeneration: Clinical Case of Low Incidence and Prevalence in Colombia. doi:10.1159/000509073 PubMed
107. [107] Linda E Klumpers et al.. J AOAC Int. 2019. A Brief Background on Cannabis: From Plant to Medical Indications. doi:10.5740/jaoacint.18-0208 PubMed
108. [108] Alexis Mitelpunkt et al.. Epilepsy Behav. 2019. The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center … doi:10.1016/j.yebeh.2019.07.007 PubMed
109. [109] Geneviève Lafaye et al.. Addict Biol. 2019. Cannabidiol affects circadian clock core complex and its regulation in microglia cells. doi:10.1111/adb.12660 PubMed
110. [110] David J Casarett et al.. J Palliat Med. 2019. Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms. doi:10.1089/jpm.2018.0658 PubMed
111. [111] Donald I Abrams. Curr Treat Options Oncol. 2019. Should Oncologists Recommend Cannabis? doi:10.1007/s11864-019-0659-9 PubMed
112. [112] Laura Weinkle et al.. Mult Scler Relat Disord. 2019. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. doi:10.1016/j.msard.2018.11.022 PubMed
113. [113] Natalia Szejko et al.. Med Cannabis Cannabinoids. 2019. Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome. doi:10.1159/000496355 PubMed
114. [114] Karen Hande. Clin J Oncol Nurs. 2019. Cannabidiol: The Need for More Information About Its Potential Benefits and Side Effects. doi:10.1188/19.CJON.131-134 PubMed
115. [115] Andrew Penn. J Psychosoc Nurs Ment Health Serv. 2019. Cannabinoids and Mental Health, Part 2: The Search for Clinical Applications. doi:10.3928/02793695-20190919-02 PubMed
116. [116] Jacob Teitelbaum. Altern Ther Health Med. 2019. A Hemp oil, CBD, and Marijuana Primer: Powerful Pain, Insomnia, and Anxiety-relieving Tools! PubMed
117. [117] . Med Lett Drugs Ther. 2019. Cannabis and cannabinoids. PubMed
118. [118] Jacob M Vigil et al.. Medicines (Basel). 2018. Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia under Naturalistic Conditions. doi:10.3390/medicines5030075 PubMed
119. [119] Kimberly A Babson et al.. Curr Psychiatry Rep. 2017. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. doi:10.1007/s11920-017-0775-9 PubMed
120. [120] Scott Shannon et al.. Perm J. 2016. Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. doi:10.7812/TPP/16-005 PubMed
121. [121] Nancy A Haug et al.. Cannabis Cannabinoid Res. 2016. Training and Practices of Cannabis Dispensary Staff. doi:10.1089/can.2016.0024 PubMed
122. [122] Sandra E Reznik et al.. Int J Infect Dis. 2016. Cannabidiol: a potential treatment for post Ebola syndrome? doi:10.1016/j.ijid.2016.09.020 PubMed
123. [123] Katherine A Belendiuk et al.. Addict Behav. 2015. Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users. doi:10.1016/j.addbeh.2015.06.032 PubMed
124. [124] Sabra M Abbott et al.. Mov Disord Clin Pract. 2014. Sleep Disorders in Atypical Parkinsonism. doi:10.1002/mdc3.12025 PubMed
125. [125] J A S Crippa et al.. J Clin Pharm Ther. 2013. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. doi:10.1111/jcpt.12018 PubMed
126. [126] Pál Pacher. Br J Pharmacol. 2013. Towards the use of non-psychoactive cannabinoids for prostate cancer. doi:10.1111/j.1476-5381.2012.02121.x PubMed
127. [127] Jeremy R Johnson et al.. J Pain Symptom Manage. 2013. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in … doi:10.1016/j.jpainsymman.2012.07.014 PubMed
128. [128] Simon Zhornitsky et al.. Pharmaceuticals (Basel). 2012. Cannabidiol in humans-the quest for therapeutic targets. doi:10.3390/ph5050529 PubMed
129. [129] Yi-Tse Hsiao et al.. Neuropharmacology. 2012. Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in … doi:10.1016/j.neuropharm.2011.08.013 PubMed
130. [130] A Seidler et al.. Occup Med (Lond). 2012. Systematic review: Progression of beryllium sensitization to chronic beryllium disease. doi:10.1093/occmed/kqs069 PubMed
131. [131] Ashish M Kamat et al.. Urol Clin North Am. 2002. Chemoprevention of bladder cancer. doi:10.1016/s0094-0143(02)00022-8 PubMed